Brendan Teehan - 17 Nov 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

SEC form
4
Accepted by SEC
17 Nov 2026, 16:36:46 UTC
Prior SEC filing
13 Feb 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Brendan Teehan filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 17 Nov 2026.

Key facts

  • This page summarizes Brendan Teehan's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 17 Nov 2026, 16:36.

Change

  • Previous filing in this sequence was filed on 13 Feb 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001891900 Primary reporting owner

Teehan Brendan

Relationship
Chief Commercial Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCRX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-100,934
Change %
-100%
Price
$36.50*
Shares after
0
Date
17 Nov 2026
Ownership
Direct
Footnotes
F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCRX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-99,500
Change %
-100%
Price
Shares after
0
Date
17 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
99,500
Exercise price
$26.59
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Brendan Teehan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.

Footnote F2

Includes 728.896 Shares acquired in June 2026 and 267.272 Shares acquired in November 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Footnote F3

Includes restricted stock unit awards ("RSUs"). Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .